Table 1.
Clinical Characteristics of the Subjects.
| Variable | Historical control (n = 20) |
BM-MNC implantation (n = 30) |
P value |
|---|---|---|---|
| Age, yr | 65.4 ± 10.2 | 67.2 ± 9.2 | 0.51 |
| Gender, men/women | 16/4 | 19/11 | 0.35 |
| Body mass index, kg/m2 | 23.8 ± 4.1 | 22.0 ± 3.5 | 0.11 |
| Rutherford category, n (%) | N.A. | ||
| 3 | 0 (0) | 1 (3) | |
| 4 | 1 (5) | 9 (30) | |
| 5 | 10 (50) | 15 (50) | |
| 6 | 9 (45) | 5 (17) | |
| Medical history, n (%) | |||
| Hypertension | 19 (95) | 26 (87) | 0.64 |
| Dyslipidemia | 10 (50) | 18 (60) | 0.57 |
| Diabetes mellitus | 19 (95) | 25 (83) | 0.38 |
| Previous myocardial infarction | 12 (60) | 15 (50) | 0.57 |
| Previous stroke | 7 (35) | 8 (27) | 0.55 |
| Chronic kidney disease | 13 (65) | 14 (47) | 0.25 |
| Hemodialysis | 9 (45) | 8 (27) | 0.23 |
| Smoker (pre) | 15 (75) | 13 (43) | 0.04 |
| Medications, n(%) | |||
| Anti-coagulant | 6 (30) | 11 (37) | 0.76 |
| Anti-platelets | 16 (80) | 24 (80) | 1.00 |
| ACE inhibitors | 1 (5) | 5 (17) | 0.38 |
| ARBs | 7 (35) | 12 (40) | 0.77 |
| Calcium-channel blockers | 5 (25) | 13 (43) | 0.24 |
| Statins | 8 (40) | 7 (23) | 0.23 |
| Sulfonylurea/metformin/other | 9 (45) | 11 (37) | 0.57 |
| Insulin | 10 (50) | 6 (20) | 0.03 |
BM-MNC indicates bone-marrow mononuclear cell; ACE, Angiotensin-converting enzyme; ARB, Angiotensin II receptor blocker.